NCT01016730 is a Phase 1 clinical trial of Bortezomib in AIDS-Related Kaposi Sarcoma, sponsored by National Cancer Institute (NCI).

Who is sponsoring NCT01016730?

NCT01016730 is sponsored by National Cancer Institute (NCI).

What drugs are being tested in NCT01016730?

Interventions in NCT01016730: Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration.

What condition does NCT01016730 study?

NCT01016730 studies AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma.

Is NCT01016730 still recruiting?

NCT01016730 is currently completed. Last updated 20 February 2018.

Last reviewed 2018-02-20 · How we verify

NCT01016730

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

Completed Phase 1 Last updated 20 February 2018

What this trial tests

Phase 1 trial testing Bortezomib in AIDS-Related Kaposi Sarcoma in 24 participants. Completed in 7 January 2015.

Timeline

22 January 2010

Primary endpoint
7 January 2015

7 January 2015

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	22 January 2010
Primary completion	7 January 2015
Estimated completion	7 January 2015
Sites	9 locations across United States

Drugs / interventions tested

Bortezomib (bortezomib) — full drug profile →
Laboratory Biomarker Analysis — full drug profile →
Questionnaire Administration

Conditions studied

AIDS-Related Kaposi Sarcoma — all drugs for AIDS-Related Kaposi Sarcoma →
HIV Infection — all drugs for HIV Infection →
Recurrent Kaposi Sarcoma — all drugs for Recurrent Kaposi Sarcoma →

Sponsor

National Cancer Institute (NCI)

Who can join

18 and older, any sex, with AIDS-Related Kaposi Sarcoma or HIV Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pilot, phase I trial studies the side effects and best dose of bortezomib in treating patients with acquired immune deficiency syndrome (AIDS)-related Kaposi sarcoma that has come back or has not responded to treatment. Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Viral Oncology: Molecular Biology and Pathogenesis.
Mui UN, Haley CT, Tyring SK. · · 2017 · cited 120× · PMID 29186062 · DOI 10.3390/jcm6120111
A Non-Coding RNA Network Involved in KSHV Tumorigenesis.
Naipauer J, García Solá ME, Salyakina D, Rosario S, et al · · 2021 · cited 12× · PMID 34222014 · DOI 10.3389/fonc.2021.687629

Verify or expand the search:

Other trials of Bortezomib

Trials testing the same drug.

NCT07513129 — A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients · Phase 1 · not yet recruiting
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07428369 — A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) · Phase 2, PHASE3 · not yet recruiting
NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
NCT07391657 — A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regi · Phase 3 · recruiting

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07012044 — A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After · Phase 1 · not yet recruiting
NCT07437950 — Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A Myel · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01016730 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute (NCI)
Last refreshed: 20 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01016730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing